一、独立董事的基本情况 青岛百洋医药股份有限公司 2024 年度独立董事述职报告 （付明仲） 作为青岛百洋医药股份有限公司（以下简称"公司"）独立董事，本人在2024 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 独立董事管理办法》《深圳证券交易所创业板股票上市规则》等有关法律、法规、 规范性文件及《公司章程》《独立董事工作制度》的规定，本着对公司及全体股 东负责的态度，恪尽职守、勤勉尽责，充分发挥独立董事参与决策、监督制衡、 专业咨询的作用，切实维护公司和全体股东特别是中小股东的权益。现将2024年 度履职情况汇报如下： （一）个人基本情况 本人付明仲，公司第三届董事会独立董事、董事会审计委员会委员、董事会 战略委员会委员、董事会提名委员会委员兼召集人。 本人付明仲，中国国籍，哈尔滨工业大学工学硕士，高级经济师、副主任药 师。曾任哈尔滨制药三厂车间副主任、质管办主任、办公室主任、副厂长、党委 委员，哈药集团董事，哈尔滨市医药公司总经理、党委书记，中国医药（集团） 公司副总经理、党委委员，中国医药集团总公司董事，中国医药工业有限公司常 务副总经理、党委委员，国药集团药业股份有限公司董 ...

青岛百洋医药股份有限公司 董事会关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等要求，青岛百洋医药股份有限公司（以下简称"公司"）董事会对公司在任独 立董事付明仲女士、陆银娣女士、郝先经先生的独立性情况进行评估并出具如下 专项意见： 经核查独立董事付明仲女士、陆银娣女士、郝先经先生的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的其他职务，未在公司 主要股东公司担任任何职务，与公司以及主要股东、实际控制人之间不存在利害 关系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的 情况。因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独 立性的相关要求。 报告人：付明仲 2025 年 4 月 22 日 青岛百洋医药股份有限公司 青岛百洋医药股份有限公司 董事会 2025 年 4 月 24 日 青岛百洋医药股份有限公司 独立董事关于 2024 年度独立性的自查 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥8.09 billion, a decrease of 1.96% compared to ¥8.26 billion in 2023[16]. - Net profit attributable to shareholders for 2024 was approximately ¥691.59 million, down 2.87% from ¥712.06 million in 2023[16]. - The net cash flow from operating activities increased by 1.80% to approximately ¥813.85 million in 2024, compared to ¥799.50 million in 2023[16]. - Total assets as of the end of 2024 reached approximately ¥7.11 billion, reflecting a growth of 10.83% from ¥6.42 billion in 2023[16]. - The company's net assets attributable to shareholders decreased by 17.85% to approximately ¥2.37 billion in 2024, down from ¥2.89 billion in 2023[16]. - The basic earnings per share for 2024 was ¥1.32, a decline of 2.94% from ¥1.36 in 2023[16]. - Non-recurring gains and losses for 2024 totaled approximately ¥35.65 million, significantly lower than ¥77.53 million in 2023[22]. - The company reported a weighted average return on net assets of 26.94% for 2024, a slight decrease from 27.25% in 2023[16]. - The company achieved a revenue of CNY 8.094 billion in 2024, and if adjusted for the two-invoice system, the revenue would be CNY 8.572 billion[44]. - The net profit attributable to shareholders was CNY 0.692 billion, with a year-on-year growth of 3.37% for the net profit excluding non-recurring gains and losses, which was CNY 0.656 billion[44]. Dividend Distribution - The company plans to distribute a cash dividend of 7.62 RMB per 10 shares to all shareholders, based on a total of 525,619,310 shares[3]. - The total distributable profit for the year is 491,619,555.98 CNY, with cash dividends accounting for 100% of the profit distribution[193]. Risks and Challenges - The company faces risks including brand operation concentration, drug quality, policy changes, and intensified market competition, which are detailed in the management discussion section[3]. - The company emphasizes the importance of risk awareness for investors regarding forward-looking statements and future plans[3]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in the audit report for the most recent year[16]. - The company emphasizes proactive measures to adapt to regulatory changes and mitigate policy risks[121]. Acquisitions and Business Development - The company completed acquisitions of several subsidiaries, including Shanghai Baiyang Pharmaceutical Co., Ltd., which were accounted for as business combinations under common control[18]. - In July 2024, the company completed the acquisition of Baiyang Pharmaceutical, enhancing its product structure and extending its industrial chain layout[28]. - The company is transitioning from a pharmaceutical commercialization platform to a platform that supports source innovation and industrialization following the acquisition[28]. - The company is focusing on expanding its pharmaceutical industry layout through the acquisition of Baiyang Pharmaceutical, enhancing its competitiveness in the industry[125]. Market Trends and Growth Potential - The Chinese pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 6.7% from 2021 to 2025, reaching a market size of 20,645 billion RMB by 2025[33]. - By the end of 2024, China's population is expected to reach 1.408 billion, with 22.0% aged 60 and above, indicating a significant market demand for healthcare services[32]. - By 2028, the Chinese innovative drug industry market size is projected to reach CNY 1.7916 trillion, indicating significant growth potential[35]. - The company is focusing on innovative drugs and high-end medical devices as new growth points, particularly in the oncology sector with the exclusive operation of a novel microtubule inhibitor[65]. Brand Operations - The company's brand operation business accounted for 68.68% of total revenue in 2024, with gross profit contribution exceeding 90%, making it the primary source of income and profit[28]. - The brand operation business achieved revenue of 5.559 billion yuan, a year-on-year increase of 9.17%, and 6.037 billion yuan when adjusted for the two-invoice system[45]. - The core brand DQ series generated revenue of 2.101 billion yuan, up 10.73% year-on-year, and 2.203 billion yuan when adjusted for the two-invoice system[45]. - The gross profit margin for the brand operation business was 48.00%, with a gross profit of 2.668 billion yuan, accounting for 92.84% of the company's total gross profit[45]. Research and Development - The company has completed all animal experiments for its project on treating pulmonary fibrosis, which is expected to broaden its product coverage[79]. - The company expanded its research on "Fuzheng Huayu" for chronic kidney disease, completing key pharmacological studies and toxicity assessments, which will enhance its product coverage and market competitiveness[80]. - The number of R&D personnel increased by 16.22% from 74 in 2023 to 86 in 2024, with a notable rise in master's degree holders by 18.18%[81]. - R&D investment amounted to ¥36,139,782.22 in 2024, representing 0.45% of operating revenue, a slight decrease from 0.51% in 2023[81]. Internal Controls and Governance - The company is committed to improving its internal control systems and has received a positive audit report on its internal controls for 2024[126]. - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[136]. - The internal control system has been improved, with no significant deficiencies identified in financial reporting controls[196]. - The company has a robust process for addressing any potential internal control deficiencies, ensuring ongoing compliance and risk management[199]. Employee Management - The total number of employees at the end of the reporting period is 3,064, with 1,535 in the parent company and 1,529 in major subsidiaries[187]. - The employee composition includes 2,243 sales personnel, 263 production personnel, and 140 financial personnel[188]. - The company has established a comprehensive training program to enhance employee skills and align personal development with corporate goals[190]. - The company maintains a competitive salary management system, linking compensation closely to performance outcomes[189].

Financial Performance - The company's revenue for Q1 2025 was CNY 1,840,874,860.51, a decrease of 0.38% compared to CNY 1,847,908,413.50 in the same period last year[5]. - Net profit attributable to shareholders was CNY 85,012,813.37, down 54.36% from CNY 186,247,923.85 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 99,966,953.05, a decrease of 39.46% compared to CNY 165,120,057.49 in the previous year[5]. - Basic earnings per share decreased by 54.29% to CNY 0.16 from CNY 0.35 year-on-year[5]. - Total operating revenue for the current period is ¥1,840,874,860.51, a slight decrease of 0.6% from ¥1,847,908,413.50 in the previous period[18]. - Net profit for the current period is ¥109,662,899.99, down 45.5% from ¥201,725,472.28 in the previous period[19]. - Earnings per share decreased to ¥0.16 from ¥0.35 in the previous period[20]. Cash Flow and Liquidity - The company's cash flow from operating activities increased by 21.23% to CNY 299,990,684.09 from CNY 247,446,648.49 in the same period last year[5]. - Cash flow from operating activities generated a net amount of ¥299,990,684.09, an increase of 21.3% compared to ¥247,446,648.49 in the previous period[21]. - The company's cash and cash equivalents increased to CNY 1,765,302,461.03 from CNY 1,467,403,220.46, representing a growth of about 20.27%[15]. - The ending balance of cash and cash equivalents was $1.58 billion, up from $1.44 billion, demonstrating a healthy liquidity position[22]. Assets and Liabilities - The company's total assets increased by 2.68% to CNY 7,302,897,907.72 from CNY 7,112,584,251.13 at the end of the previous year[5]. - The total assets of the company as of March 31, 2025, amounted to CNY 7,302,897,907.72, an increase from CNY 7,112,584,251.13 at the beginning of the period, reflecting a growth of approximately 2.67%[15]. - The total current liabilities rose to CNY 3,354,576,985.41 from CNY 3,257,963,613.64, indicating an increase of approximately 2.98%[16]. - Total liabilities increased to ¥4,588,955,377.28 from ¥4,507,912,645.50, reflecting a growth of 1.8%[17]. - Total equity attributable to shareholders increased to ¥2,460,493,402.78 from ¥2,374,910,404.59, representing a growth of 3.6%[17]. Investments and Financing - The company's long-term equity investments increased to CNY 815,362,181.60 from CNY 727,624,417.04, showing a growth of around 12.06%[15]. - The total amount of short-term borrowings increased to CNY 1,278,356,091.24 from CNY 1,098,574,415.39, marking a rise of approximately 16.37%[16]. - Cash inflows from investment activities totaled $50.15 million, down from $61.64 million, suggesting a decrease in investment income[22]. - Cash outflows for investments were $252.01 million, compared to $196.93 million, indicating increased capital expenditures[22]. - The company received $628.68 million in borrowings, significantly higher than $314.43 million in the previous period, reflecting aggressive financing strategies[22]. Operational Highlights - The core business brand operation achieved revenue of CNY 1,295,000,000, a year-on-year increase of 17.11%[8]. - The brand operation business achieved a gross profit of CNY 607,000,000, with a gross profit margin of 92.06%[8]. - The company signed a manufacturing services agreement with ZAP Surgical Systems, Inc. for the production and sale of specified products, indicating a strategic move into new product lines[13]. - A promotional agreement was established with Roche Pharmaceuticals for the exclusive promotion of a specific product, enhancing the company's market presence[13]. Shareholder Information - The company recorded a total of 16,364 common shareholders at the end of the reporting period[10]. - The largest shareholder, Baiyang Pharmaceutical Group, holds 70.22% of the shares, with 170,524,652 shares pledged[10]. Miscellaneous - The company reported a significant increase in sales expenses to ¥351,371,788.98, up 28.3% from ¥274,088,221.08 in the previous period[18]. - Investment income showed a loss of ¥8,918,355.50, contrasting with a gain of ¥8,572,990.80 in the previous period[18]. - The company did not undergo an audit for the first quarter report, which may affect the perception of financial reliability[23].

证券代码：301015 证券简称：百洋医药 公告编号：2025-023 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于子公司为子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 为满足生产经营需要，上海百洋制药股份有限公司（以下简称"百洋制药"） 全资子公司上海黄海制药有限责任公司（以下简称"黄海制药"）向南京银行股份 有限公司上海分行（以下简称"南京银行"）申请了 4,000 万元授信额度。 近日，百洋制药召开股东会会议，审议通过了为黄海制药的上述授信额度提供 连带责任保证担保的事项，并与南京银行签订了《最高额保证合同》。根据《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关规 定，本次担保属于上市公司控股子公司为公司合并报表范围内的法人提供担保，百 洋制药已履行了其内部审批程序，该事项无需经过公司董事会或股东大会审议。 | 公司名称 | 上海黄海制药有限责任公司 | | --- | --- | | 成立时间 | 1989 年 11 月 8 日 | | 注册地址 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-022 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于不向下修正百洋转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 4 月 16 日，青岛百洋医药股份有限公司（以下简称"公司"） 股票已出现任意连续三十个交易日中至少有十五个交易日的收盘价格低于当期 转股价格的 85%（即 22.20 元/股）的情形，触发"百洋转债"转股价格向下修 正条件。 2、可转债上市情况 经深圳证券交易所同意，公司 8.60 亿元可转债已于 2023 年 5 月 5 日起在深 圳证券交易所挂牌上市交易，债券简称"百洋转债"，债券代码"123194"。 3、可转债转股期限 本次发行的可转债转股期限自发行结束之日起满六个月后的第一个交易日 起至可转债到期日止，即 2023 年 10 月 20 日至 2029 年 4 月 13 日。 4、可转债转股价格调整情况 （1）"百洋转债 ...

| 证券代码：301015 | 证券简称：百洋医药 公告编号：2025-021 | | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | 鉴于"百洋转债"距离存续期届满尚远，综合考虑公司的基本情况、市场环 境、股价走势等诸多因素，以及对公司长期稳健发展与内在价值的信心，公司董 事会决定本次不向下修正"百洋转债"转股价格，同时自本次董事会审议通过次 一交易日起未来 6 个月（2025 年 4 月 17 日至 2025 年 10 月 16 日）内，如再次 触发"百洋转债"转股价格向下修正条件，亦不提出向下修正方案。在此期间之 后（从 2025 年 10 月 17 日重新起算），若再次触发"百洋转债"转股价格向下 修正条件，届时公司董事会将再次召开会议决定是否行使"百洋转债"的转股价 格向下修正权利。 青岛百洋医药股份有限公司 第三届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 青岛百洋医药股份有限公司（以下简称"公司"）第三届董事会第三十次会 议于 2025 年 4 月 16 日以 ...

| 证券代码：301015 | 证券简称：百洋医药 公告编号：2025-020 | | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | 青岛百洋医药股份有限公司 关于预计触发百洋转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、可转债上市情况 1、证券代码：301015 证券简称：百洋医药 2、债券代码：123194 债券简称：百洋转债 3、转股价格：人民币 26.12 元/股 4、转股期限：2023 年 10 月 20 日至 2029 年 4 月 13 日 经深圳证券交易所同意，公司 8.60 亿元可转债已于 2023 年 5 月 5 日起在深 圳证券交易所挂牌上市交易，债券简称"百洋转债"，债券代码"123194"。 3、可转债转股期限 本次发行的可转债转股期限自发行结束之日起满六个月后的第一个交易日 起至可转债到期日止，即 2023 年 10 月 20 日至 2029 年 4 月 13 日。 特别提示： 自 2025 年 3 月 26 日至 2025 年 4 月 9 日，青岛百洋医药 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-019 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于百洋转债 2025 年付息的公告 3、除息日：2025 年 4 月 14 日（星期一） 4、付息日：2025 年 4 月 14 日（星期一） 5、本次付息期间及票面利率：计息期间为 2024 年 4 月 14 日至 2025 年 4 月 13 日，票面利率为 0.50%。 6、"百洋转债"本次付息的债权登记日为 2025 年 4 月 11 日，截至 2025 年 4 月 11 日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司深圳 分公司（以下简称"中国结算深圳分公司"）登记在册的"百洋转债"持有人享 有本次派发的利息，在 2025 年 4 月 11 日前（含当日）申请转换成青岛百洋医药 股份有限公司（以下简称"公司"）股票的可转换公司债券（以下简称"可转债"）， 公司不再向其持有人支付本计息年度及以后计息年度的利息。 7、下一付息期起息日：2025 年 4 月 14 日 8、下一付息期 ...